Unknown

Dataset Information

0

Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients.


ABSTRACT:

Objectives

Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We performed early Health Technology Assessment of hypothetical TEHV in elderly patients (≥ 70 years) requiring surgical (SAVR) or transcatheter aortic valve implantation (TAVI) to assess the potential of TEHV and to inform future development decisions.

Methods

Using a patient-level simulation model, the potential cost-effectiveness of TEHV compared with bioprostheses was predicted from a societal perspective. Anticipated, but currently hypothetical improvements in performance of TEHV, divided in durability, thrombogenicity, and infection resistance, were explored in scenario analyses to estimate quality-adjusted life-year (QALY) gain, cost reduction, headroom, and budget impact.

Results

Durability of TEHV had the highest impact on QALY gain and costs, followed by infection resistance. Improved TEHV performance (- 50% prosthetic valve-related events) resulted in lifetime QALY gains of 0.131 and 0.043, lifetime cost reductions of €639 and €368, translating to headrooms of €3255 and €2498 per hypothetical TEHV compared to SAVR and TAVI, respectively. National savings in the first decade after implementation varied between €2.8 and €11.2 million (SAVR) and €3.2-€12.8 million (TAVI) for TEHV substitution rates of 25-100%.

Conclusions

Despite the relatively short life expectancy of elderly patients undergoing SAVR/TAVI, hypothetical TEHV are predicted to be cost-effective compared to bioprostheses, commercially viable and result in national cost savings when biomedical engineers succeed in realising improved durability and/or infection resistance of TEHV.

SUBMITTER: Huygens SA 

PROVIDER: S-EPMC7214484 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients.

Huygens Simone A SA   Ramos Isaac Corro IC   Bouten Carlijn V C CVC   Kluin Jolanda J   Chiu Shih Ting ST   Grunkemeier Gary L GL   Takkenberg Johanna J M JJM   Rutten-van Mölken Maureen P M H MPMH  

The European journal of health economics : HEPAC : health economics in prevention and care 20200125 4


<h4>Objectives</h4>Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We performed early Health Technology Assessment of hypothetical TEHV in elderly patients (≥ 70 years) requiring surgical (SAVR) or  ...[more]

Similar Datasets

| S-EPMC6261454 | biostudies-literature
| S-EPMC5545463 | biostudies-other
| S-EPMC7278207 | biostudies-literature
| S-EPMC10941672 | biostudies-literature
| S-EPMC5056004 | biostudies-literature
| S-EPMC8691673 | biostudies-literature
| S-EPMC11913896 | biostudies-literature
| S-EPMC8649494 | biostudies-literature
2018-02-01 | GSE108083 | GEO
| S-EPMC4112351 | biostudies-other